Amneal Pharmaceuticals (AMRX) Set to Announce Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $5.90 on Friday. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -19.03 and a beta of 1.33. Amneal Pharmaceuticals has a twelve month low of $1.64 and a twelve month high of $6.46. The company has a quick ratio of 0.94, a current ratio of 1.63 and a debt-to-equity ratio of 121.31. The company has a 50 day moving average of $5.72 and a two-hundred day moving average of $5.18.

Analysts Set New Price Targets

Several equities research analysts have weighed in on AMRX shares. Piper Sandler raised their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. The Goldman Sachs Group raised their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research note on Monday, March 4th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Barclays raised their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.